Brain metastases represent one of the most feared complications in lung cancer — they erode cognition, independence, and survival prospects simultaneously. For the roughly one-third of patients with EGFR-mutated non-small cell lung cancer who develop them, the question of whether to add radiation to an already-effective targeted agent has remained genuinely unresolved. This meta-analysis, drawing on nearly 15,000 patients, offers the clearest quantitative answer yet.
The analysis synthesized 10 randomized controlled trials and 17 observational studies totaling 14,955 patients. Third-generation EGFR tyrosine kinase inhibitors — predominantly osimertinib — achieved CNS objective response rates between 60% and 91%, substantially outperforming earlier-generation agents. Critically, combining EGFR-TKI therapy with radiotherapy — whether stereotactic radiosurgery or whole-brain radiation — yielded superior local control and overall survival compared with TKI monotherapy. This benefit was most pronounced in a defined patient subset: those with fewer than three brain metastases, ECOG performance status 0–2, and moderate-to-severe neurological symptom burden at baseline.
The finding challenges a clinical drift that had emerged following osimertinib's approval — the assumption that CNS penetrance potent enough to produce 91% response rates might render radiation redundant. This data suggests the two modalities are additive rather than substitutable, at least in oligometastatic CNS disease. The limitation worth flagging is considerable: pooling randomized and observational data across 27 studies introduces substantial heterogeneity in treatment protocols, staging criteria, and follow-up duration. Osimertinib's dominance in the dataset is also relatively recent, meaning survival curves may not yet reflect its full impact. The patient selection criteria that predicted benefit — oligometastatic burden and preserved functional status — align closely with existing stereotactic radiosurgery guidelines, lending biological plausibility to the combination signal. For oncology practice, this represents confirmatory but genuinely important evidence that combination sequencing decisions should remain individualized rather than protocol-collapsed.